Circulating MiRNAs Respond to Denosumab Treatment After 2 Years in Postmenopausal Women With Osteoporosis-the MiDeTe Study

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2022 Nov 21

PMID 36408612

Authors

Zora Messner

David Carro Vazquez

Judith Haschka

Johannes Grillari

Heinrich Resch

Christian Muschitz

Peter Pietschmann

Jochen Zwerina

Matthias Hackl

Roland Kocijan

Affiliations

Soon will be listed here.

Abstract

Context: MicroRNAs (miRNAs)-short, single-stranded, noncoding RNAs-regulate several biological processes, including bone metabolism.

Objective: We investigated circulating miRNAs as promising biomarkers for treatment monitoring in women with postmenopausal osteoporosis on denosumab (DMAB) therapy.

Methods: In this prospective, observational, single-center study, 21 postmenopausal women treated with DMAB were included for a longitudinal follow-up of 2 years. Next-generation sequencing (NGS) was performed to screen for serological miRNAs at baseline, month 6, and month 24. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to confirm NGS findings in the entire cohort. Bone turnover markers (BTM) P1NP and CTX, and bone mineral density (BMD) by dual x-ray absorptiometry were assessed and correlated to miRNAs.

Results: BMD at the hip (5.5%, P = 0.0006) and lumbar spine significantly increased (11.4%, P = 0.017), and CTX (64.1%, P < 0.0001) and P1NP (69.3%, P < 0.0001) significantly decreased during treatment. NGS analysis revealed significant changes in miRNAs after 2 years of DMAB treatment but not after 6 months. Seven miRNAs were confirmed by RT-qPCR to be significantly changed during a 2-year course of DMAB treatment compared to baseline. Four of these were mainly transcribed in blood cells, including monocytes. Correlation analysis identified significant correlation between change in miRNA and change in BTMs as well as BMD. Based on effect size and correlation strength, miR-454-3p, miR-26b-5p, and miR-584-5p were defined as top biomarker candidates, with the strongest association to the sustained effect of denosumab on bone in osteoporotic patients.

Conclusion: Two years of DMAB treatment resulted in upregulation of 7 miRNAs, 4 of which are mainly transcribed in monocytes, indicating a potential impact of DMAB on circulating osteoclast precursor cells. These changes were associated to BMD gain and BTM suppression and could therefore be useful for monitoring DMAB treatment response.

Citing Articles

Therapeutic applications of miRNA in the management of obesity and osteoporosis.

Abolhasani S, Ahmadi Y, Rostami Y, Zendeh M, Fattahi D J Diabetes Metab Disord. 2025; 24(1):75.

PMID: 40041677 PMC: 11876508. DOI: 10.1007/s40200-025-01589-6.

The Role of microRNA in the Regulation of Differentiation and the Functionality of Osteoblasts, Osteoclasts, and Their Precursors in Osteoporosis.

Yalaev B, Kaletnik E, Karpova Y, Belaya Z, Minniakhmetov I, Mokrysheva N Noncoding RNA. 2025; 11(1).

PMID: 39997614 PMC: 11858178. DOI: 10.3390/ncrna11010014.

From Genomics to Metabolomics: Molecular Insights into Osteoporosis for Enhanced Diagnostic and Therapeutic Approaches.

Li Q, Wang J, Zhao C Biomedicines. 2024; 12(10).

PMID: 39457701 PMC: 11505085. DOI: 10.3390/biomedicines12102389.

Longitudinal course of circulating miRNAs in a patient with hypophosphatasia and asfotase alfa treatment: a case report.

Hadzimuratovic B, Haschka J, Hackl M, Diendorfer A, Mittelbach A, Feurstein J JBMR Plus. 2024; 8(10):ziae107.

PMID: 39224569 PMC: 11366046. DOI: 10.1093/jbmrpl/ziae107.

The Involvement of microRNAs in Bone Remodeling Signaling Pathways and Their Role in the Development of Osteoporosis.

Jimenez-Ortega R, Ortega-Melendez A, Patino N, Rivera-Paredez B, Hidalgo-Bravo A, Velazquez-Cruz R Biology (Basel). 2024; 13(7).

PMID: 39056698 PMC: 11273958. DOI: 10.3390/biology13070505.

References

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Weber J, Baxter D, Zhang S, Huang D, Huang K, Lee M . The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56(11):1733-41. PMC: 4846276. DOI: 10.1373/clinchem.2010.147405. View

Alles J, Fehlmann T, Fischer U, Backes C, Galata V, Minet M . An estimate of the total number of true human miRNAs. Nucleic Acids Res. 2019; 47(7):3353-3364. PMC: 6468295. DOI: 10.1093/nar/gkz097. View

Kocijan R, Weigl M, Skalicky S, Geiger E, Ferguson J, Leinfellner G . MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis. Bone. 2019; 131:115104. DOI: 10.1016/j.bone.2019.115104. View

Lee R, Feinbaum R, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. DOI: 10.1016/0092-8674(93)90529-y. View

Metsalu T, Vilo J . ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 2015; 43(W1):W566-70. PMC: 4489295. DOI: 10.1093/nar/gkv468. View

Khamina K, Diendorfer A, Skalicky S, Weigl M, Pultar M, Krammer T . A MicroRNA Next-Generation-Sequencing Discovery Assay (miND) for Genome-Scale Analysis and Absolute Quantitation of Circulating MicroRNA Biomarkers. Int J Mol Sci. 2022; 23(3). PMC: 8835905. DOI: 10.3390/ijms23031226. View

Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Teilum M . Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2012; 59(1):S1-6. DOI: 10.1016/j.ymeth.2012.09.015. View

Hackl M, Heilmeier U, Weilner S, Grillari J . Circulating microRNAs as novel biomarkers for bone diseases - Complex signatures for multifactorial diseases?. Mol Cell Endocrinol. 2015; 432:83-95. DOI: 10.1016/j.mce.2015.10.015. View

10.

. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285(6):785-95. DOI: 10.1001/jama.285.6.785. View

11.

Weigl M, Kocijan R, Ferguson J, Leinfellner G, Heimel P, Feichtinger X . Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis. J Bone Miner Res. 2021; 36(6):1131-1144. PMC: 8252367. DOI: 10.1002/jbmr.4276. View

12.

Mussbacher M, Krammer T, Heber S, Schrottmaier W, Zeibig S, Holthoff H . Impact of Anticoagulation and Sample Processing on the Quantification of Human Blood-Derived microRNA Signatures. Cells. 2020; 9(8). PMC: 7464075. DOI: 10.3390/cells9081915. View

13.

Turchinovich A, Weiz L, Burwinkel B . Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012; 37(11):460-5. DOI: 10.1016/j.tibs.2012.08.003. View

14.

Xu X, Zhang P, Li X, Liang Y, Ouyang K, Xiong J . MicroRNA expression profiling in an ovariectomized rat model of postmenopausal osteoporosis before and after estrogen treatment. Am J Transl Res. 2020; 12(8):4251-4263. PMC: 7476138. View

15.

Keller A, Groger L, Tschernig T, Solomon J, Laham O, Schaum N . miRNATissueAtlas2: an update to the human miRNA tissue atlas. Nucleic Acids Res. 2021; 50(D1):D211-D221. PMC: 8728130. DOI: 10.1093/nar/gkab808. View

16.

Kocijan R, Muschitz C, Geiger E, Skalicky S, Baierl A, Dormann R . Circulating microRNA Signatures in Patients With Idiopathic and Postmenopausal Osteoporosis and Fragility Fractures. J Clin Endocrinol Metab. 2016; 101(11):4125-4134. DOI: 10.1210/jc.2016-2365. View

17.

Muschitz C, Hummer M, Grillari J, Hlava A, Birner A, Hemetsberger M . Epidemiology and economic burden of fragility fractures in Austria. Osteoporos Int. 2021; 33(3):637-647. PMC: 8497183. DOI: 10.1007/s00198-021-06152-6. View

18.

Paschalis E, Krege J, Gamsjaeger S, Eriksen E, Burr D, Disch D . Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Assessment Techniques. J Bone Miner Res. 2018; 33(12):2230-2235. DOI: 10.1002/jbmr.3565. View

19.

Grillari J, Makitie R, Kocijan R, Haschka J, Carro Vazquez D, Semmelrock E . Circulating miRNAs in bone health and disease. Bone. 2020; 145:115787. DOI: 10.1016/j.bone.2020.115787. View

20.

de Rie D, Abugessaisa I, Alam T, Arner E, Arner P, Ashoor H . An integrated expression atlas of miRNAs and their promoters in human and mouse. Nat Biotechnol. 2017; 35(9):872-878. PMC: 5767576. DOI: 10.1038/nbt.3947. View